巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Aptinyx

    APTX
    0.538
    0.020
    3.98%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Aptinyx - 延遲價格・最後更新於 05/07 12:15
    最高位
    0.554
    最低位
    0.480
    開市價
    --
    前收市價
    0.560
    成交量(千)
    3.33
    成交額(百萬)
    0.02
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    36.43
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.760 - 0.360
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Aptinyx
    證券代碼
    APTX.US
    所屬板塊
    Biotechnology
    公司業務
    Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
    發行量
    67715718
    公司總部
    909 Davis Street, Suite 600
    公司網址
    https://www.aptinyx.com
    公司電郵
    corporate@aptinyx.com
    公司電話
    +1 847 871-0377
    暫無內容

    關於

    Aptinyx(APTX.US)所屬的行業板塊為Biotechnology。
    Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
    詳細公司背景可參考: https://www.aptinyx.com